BLFS

Business Context and Reporting Period

Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: BioLife develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry, focusing on biopreservation, cell processing, and automated thawing. The company operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 25% year-over-year, driven primarily by higher demand for biopreservation media products.
• Margin Compression: Gross margin decreased 3 percentage points to 64% due to a less favorable product mix and increased sales of lower-margin items.
• Operating Expenses: Total operating expenses rose 14% to $17.5 million. Research and Development (R&D) expenses surged 84% to $2.7 million, largely due to increased headcount from the PanTHERA acquisition. General and Administrative (G&A) expenses increased 8% due to personnel and stock-based compensation costs.
• Profitability: The company returned to profitability with $1.2 million in net income, compared to a net loss of $0.45 million in Q1 2025. This improvement was aided by a $1.2 million increase in other income (primarily interest income) and the absence of discontinued operation losses in the current period.
• Cash Position: Cash and cash equivalents decreased by $10.2 million to $22.8 million. This reduction was driven by net cash used in operating activities ($0.5 million), investing activities ($1.8 million), and financing activities ($7.9 million).

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current liquid assets ($111.5 million) are sufficient to meet liquidity needs for at least the next 12 months.
• Acquisitions & Divestitures:
  • PanTHERA: Completed acquisition of remaining 90% interest in April 2025 for $16.8 million. The acquired IRI GEN 2 technology was expensed immediately as in-process R&D ($15.5 million). An earnout of up to $7.2 million is possible based on future revenue targets, though management currently deems achievement remote.
  • SAVSU Divestiture: Completed in Q4 2025. The business is reported as discontinued operations. The company recognized a $10.3 million gain on disposal in the prior period.
• Debt Maturity: The company has a Term Loan with a maturity date of June 1, 2026. The remaining principal balance is $2.5 million, classified as current debt.
• Accounting Changes: The company changed its inventory valuation method to a weighted average costing method for all inventories as of March 31, 2026. This change was not material to financial results.
• Risks: Risks include global economic uncertainty, tariff impacts, high interest rates, and the realization of deferred tax assets (currently fully reserved with a $45.3 million valuation allowance).

Investor Verification Checklist

• Debt Maturity: Verify the repayment plan for the $2.5 million Term Loan maturing June 1, 2026, given the current cash balance of $22.8 million.
• Working Capital Trends: Monitor the increase in Accounts Receivable (up $5.1 million) and Inventories (up $2.7 million) which contributed to negative operating cash flow.
• Stock-Based Compensation: Review the $4.8 million in stock-based compensation expense and the $20.2 million in unrecognized costs, which will impact future earnings.
• Product Mix: Assess the sustainability of revenue growth given the 3% decline in gross margin attributed to lower-margin product sales.
• Discontinued Operations: Confirm no further liabilities or transition service obligations remain from the SAVSU divestiture or prior SciSafe/Global Cooling divestitures.